Cayston is a drug owned by Gilead Sciences Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 20, 2021. Details of Cayston's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8399496 | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) |
Expired
|
| US7208141 | Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) |
Expired
|
| US7214364 | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) |
Expired
|
| US7427633 | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
Dec, 2021
(2 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cayston's patents.
Latest Legal Activities on Cayston's Patents
Given below is the list of recent legal activities going on the following patents of Cayston.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Mar, 2020 | US7427633 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Nov, 2018 | US7214364 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Oct, 2018 | US7208141 |
| Notice of Final Determination- Ineligible | 31 Mar, 2015 | US7208141 |
| Notice of Final Determination- Ineligible | 31 Mar, 2015 | US7214364 |
| Notice of Final Determination- Ineligible | 31 Mar, 2015 | US7427633 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 21 Jun, 2013 | US7214364 |
| Letter from FDA or Dept of Agriculture re PTE application | 05 Mar, 2012 | US7214364 |
| Letter from FDA or Dept of Agriculture re PTE application | 05 Mar, 2012 | US7208141 |
| Mail-Record Petition Decision of Granted Related to Inventor in Patent | 29 Dec, 2011 | US7427633 |
FDA has granted several exclusivities to Cayston. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Cayston, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Cayston.
Exclusivity Information
Cayston holds 1 exclusivities. All of its exclusivities have expired in 2017. Details of Cayston's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Feb 22, 2017 |
US patents provide insights into the exclusivity only within the United States, but Cayston is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cayston's family patents as well as insights into ongoing legal events on those patents.
Cayston's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cayston's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 20, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cayston Generics:
Aztreonam is the generic name for the brand Cayston. 3 different companies have already filed for the generic of Cayston, with Fresenius Kabi Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cayston's generic
About Cayston
Cayston is a drug owned by Gilead Sciences Inc. It is used for improving respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston uses Aztreonam as an active ingredient. Cayston was launched by Gilead in 2010.
Approval Date:
Cayston was approved by FDA for market use on 22 February, 2010.
Active Ingredient:
Cayston uses Aztreonam as the active ingredient. Check out other Drugs and Companies using Aztreonam ingredient
Treatment:
Cayston is used for improving respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.
Dosage:
Cayston is available in for solution form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 75MG/VIAL | FOR SOLUTION | Prescription | INHALATION |